Can a single dose of radiation during surgery improve pancreatic cancer outcomes?

NCT ID NCT05141513

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This trial is testing whether giving a single dose of radiation directly to the tumor area during surgery is safe for people with localized pancreatic cancer. Participants first receive standard chemotherapy and stereotactic body radiation therapy (SBRT), then at the time of surgical removal, they receive intraoperative radiation therapy (IORT). The study aims to evaluate the short-term and long-term side effects of this additional radiation, with the hope of improving local control of the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Intraoperative radiation therapy (IORT) using high-dose-rate brachytherapy
What this could lead to
If safe and effective, this approach could improve local control of pancreatic cancer after surgery, potentially extending survival or delaying recurrence.
What could go wrong
This is an early-phase safety study with a small number of participants. The added radiation may increase post-operative complications, and the benefit over standard care is not yet established.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALIZED PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Johns Hopkins Hospital

    Baltimore, Maryland, 21205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.